MDT Diabetes

Quote

















Tandem says they will triple their install base. Stock way up. This will all come at the expense of Medtronic. Diabetes division is DOA. Remember when Tandem stock price was under a dollar and they were ready to go belly up? Roles now reversed.

Bad strategy and worse leadership from Medtronic to lose what it had should be a case study in business schools as to what not to do.

Shameful. #USUCK
 
















Diabetes division should be sold to a competitor that understands the business and the patient needs and requests. Out of touch product development and leadership not delivering on strategy and product ease of use doomed division years ago. No finger sticks is the standard. Quality concerns has been and is a big issue.
 








anonymous said:
Diabetes division should be sold to a competitor that understands the business and the patient needs and requests. Out of touch product development and leadership not delivering on strategy and product ease of use doomed division years ago. No finger sticks is the standard. Quality concerns has been and is a big issue.
Click to expand...

The precedent is set with LVADs - when it becomes unethical to keep selling an inferior product, time to shut it down.
 
















Doctor: “Now I prescribe Dexcom or Libre and I never have to hear my patients complaining about non stop finger sticks. My day just got better.”

Happens every day. Not sure why Medtronic hasn’t figured that out yet. That’s the biggest reason we’re so out of touch and will be shutting this division down.
 








anonymous said:
Diabetes division should be sold to a competitor that understands the business and the patient needs and requests. Out of touch product development and leadership not delivering on strategy and product ease of use doomed division years ago. No finger sticks is the standard. Quality concerns has been and is a big issue.
Click to expand...
Who wants it? Competitors have no need for inferior technology, and any private equity buyer will see the dwindling patient base and flee. This is much closer to the JNJ Animas business (lots of work, big investment, little return) than the JNJ LifeScan business (not high growth,but printing money).
 
















































































anonymous said:
nail in the coffin. Mdt stock price down 6% from this news. Both competitors stock price goes up. 780g was the ace up the sleeve to keep Diabetes remotely relevant, but won’t see that anytime soon with this
Click to expand...

According to MG, several pumps have launched during a warning letter. I say maybe but this is not helping. They say they have the best sales force but they let go senior people who were doing well and being in 4th and 5th stringers. Unbelievable. How are they paying this many reps in the field and how are clinical people even busy with few shipments?
 








MG and management will say half truths and spin to minimize. Talk is cheap. Does any think the Northridge is trusted
Lowering US sales was projected in press release as the spin machine cant fool anyone anymore. Stock near 52 week low in market up 30%. Underwateer on 15% stock discount. Thanks
 








Top Bottom
Back
Quote